Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Marcello Allegretti has a total of 504 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    rhNGF shows neuroprotective efficacy by counteracting oxidative stress and neuroinflammation in a glaucoma mouse model

    by Davide Vecchiotti, Mauro Di Vito Nolfi, Chiara Compagnoni, Martina Sara Miscione, Daniela Verzella, Daniel D’ANdrea, Irene Flati, Francesca Galli, Michele D’ANgelo, Adriano Angelucci, et al.

    Glaucoma is a neurodegenerative condition characterised by the progressive loss of retinal ganglion cells (RGCs) and irreversible vision impairment and one of the leading causes of blindness worldwide. Current treatments primarily focus on reducing intraocular pressure (IOP), yet many patients continue to experience disease progression. Neurotrophin-based therapies, such as recombinant human nerve growth factor (rhNGF), offer a promising candidate alternative by directly targeting neuronal survival mechanisms. In this study, we evaluated the neuroprotective efficacy of a single intravitreal administration of rhNGF in a well-established genetic murine model of spontaneous pigmentary glaucoma, assessing its effects on visual function, retinal morphology, metabolism, oxidative stress, and inflammation. Our results demonstrate that rhNGF ameliorates visual acuity loss, preserves retinal thickness, sustains RGC survival, and reduces oxidative stress and neuroinflammation both in early-stage and fully developed disease. Notably, these protective effects persisted for several weeks after a single intravitreal administration. Collectively, our findings support rhNGF as a multifaceted neuroprotective approach to hamper glaucomatous damage.

  • Open Access

    Inflammatory networks between adipose tissue, liver and pancreatic islets in type 2 diabetes

    by Maria Inês Farrim, Diogo Silva, Andreia Gomes, Lidia De Filippis, Georgia Fousteri, Andrea Aramini, Marcello Allegretti, Dragan Milenkovic, Regina Menezes, Rafael Cypriano Dutra


  • Open Access

    Raloxifene and tamoxifen reshape the immunometabolic phenotype of TLRs-activated macrophages through AEBS inhibition and lysosomal stress

    by Chiara Sfogliarini, Camilla Bernardinelli, Lien Hong Tran, Paola Antonia Corsetto, Angela Maria Rizzo, Franca Cattani, Maria Candida Cesta, Marcello Allegretti, Sara Della Torre, Massimo Locati, et al.

  • Open Access

    Shp1 phosphatase regulates CXCR2 protein stability and IL8-mediated invasiveness in breast cancer

    by Marcello Monti, Pier Giorgio Amendola, Angela Filograna, Sabrina Gargiulo, Marcello Allegretti, Daniela Corda, Alessia Varone

    Shp1 is a cytosolic tyrosine phosphatase generally associated with antitumor effects through the inhibition of tyrosine kinase signaling. Herein, we shown that genetic and pharmacological inhibition of Shp1 in breast cancer cells induces accelerated cell migration and promotes a more invasive phenotype. Furthermore, we found that interleukin-8 (IL8), a chemokine with multiple pro-tumorigenic roles within the tumor microenvironment, directly modulates Shp1 activity. In breast cancer, IL8 elicits its functions through the binding to the CXCR2 receptor with the subsequent modulation of several intracellular signaling pathways. We show that in breast MCF7 cells, IL8 induces the PKC-mediated phosphorylation of Shp1 at Ser591, diminishing its enzymatic activity and impairing the dephosphorylation of PP2A; this enhances CXCR2 phosphorylation and alters receptor trafficking by promoting ubiquitination and degradation of CXCR2. This feedback mechanism limits IL8 signaling revealing a previously unrecognized mechanism of receptor turnover and signal attenuation. In addition, we found that Shp1-mediated regulation of CXCR2 directly influences IL8-driven invasiveness in a subtype-specific manner, affecting luminal and triple-negative breast cancer (TNBC) cells but not HER2-positive ones. Transcriptomic and pathway analyses further support Shp1 involvement in cytokine and GPCR signaling, particularly in TNBC, where its downregulation correlates with reduced survival and higher IL8 levels. Taken together, our findings elucidate a novel mechanism of IL8 signaling and identify Shp1 as a promising therapeutic target, highlighting the potential of modulating the CXCR2–Shp1 axis to limit invasiveness and metastasis in aggressive breast cancer subtypes, particularly TNBC.

  • Open Access

    Viral Infections and Dysregulation of Neurotrophin Signaling: Potential impact in the Central Nervous System

    by Mariya Timotey Miteva, Virginia Protto, Francesco Zanzi, Maria Candida Cesta, Marcello Allegretti, Giovanna De Chiara

  • Open Access

    Ladarixin Potential over the Effects of IL-8 and of Serum from Patients with Abdominal Aortic Aneurysm on Human Aortic Cells

    by Lucia Spartano, Maria Lombardi, Vincenzo Ardita, Roberto Chiesa, Andrea Aramini, Marcello Allegretti, Domenico Baccellieri, Lidia De Filippis, Chiara Foglieni

    Early cellular alterations in abdominal aortic aneurysm (AAA) are scarcely investigated. Aortic remodeling inflammation-related suggested the CXCR2/CXCL1/IL-8 axis as a therapeutic target. This study investigates CXCR1/CXCR2 antagonism in primary human aortic endothelial (HAOEC) and smooth muscle cells (HAOSMC) conditioned with IL-8 or serum from patients with AAA (sPT). Ladarixin (10 μM Lad or 25 μM) served as an inhibitor. Readouts included RT-qPCR for CXCL1, CXCL8, CXCR2, MMP9, NFKB1, and VEGF-A; zymography for MMP9 activity confocal microscopy for F-actin and mitochondria; NADPH/NADH diaphorase histochemistry for redox activity; and ATP assay. In HAOEC, IL-8 downregulated CXCR2, increased MMP9 activity, and induced cytoskeletal and mitochondria disorganization without altering NADH/NADPH diaphorases but increasing ATP release. At concentration of 10 μM Lad rescued cell organization and gene expression. sPT upregulated CXCL8, CXCR2, and MMP9, decreased NADH/NADPH diaphorases, and altered cytoskeleton and mitochondria organization in HAOEC. At concentration of 10 μM Lad (partially) and 25 μM Lad reverted gene upregulation and mitochondria distribution; both doses increased diaphorase and released ATP. HAOSMC were scantily susceptible to IL-8 and weakly responsive to sPT, slightly upregulating CXCR2 and VEGF-A but increasing proMMP9 gelatinolysis. Ladarixin recovered proMMP9 activity and modulated CXCL1. AAA-like vascular cell alterations involve multiple inflammatory factors and are modulable by inhibition of IL-8 receptors. The results underline careful dose calibration.


  • Open Access

    Validation of the FACIT-Fatigue scale in patients with locally advanced or metastatic breast cancer

    by Alessandra Fabi, Steven Hager, Laura Lourdes, Chiara Gandini, Elizabeth M Gavioli, Renuka Wakade, Enrico M Minnella, Marcello Allegretti

    Background: Cancer-related fatigue (CRF) is a common symptom in patients with locally advanced or metastatic breast cancer (LA/M BC) receiving taxane-based chemotherapy (CT). CRF is commonly assessed as a subjective experience by patient questionnaires, such as the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue. The aim of this study was to extend the validity of the FACIT-Fatigue and estimate clinically meaningful group-level differences in this patient population. Materials and methods: This was a prospective, noninterventional, multinational study conducted in the United States and Italy from October 2021 to August 2023 in adult patients with LA/M BC eligible to receive cycle 1 of taxane-based CT. Patients completed a FACIT-Fatigue survey before starting CT and every 3 to 4 weeks for ∼16 weeks; a group of patients participated in a qualitative substudy to explore additional fatigue factors via semistructured, phone-based cognitive interviews. Results: Sixty-two female patients with a mean (standard deviation) age of 55.5 (12.2) years were included. Baseline (visit 1) mean (95% confidence interval) FACIT-Fatigue score was 39.0 (36.8, 41.2), and fatigue worsened over time from 36.6 at visit 2 to 31.9 at visit 5. All FACIT-Fatigue items were relevant, with patients frequently reporting physical and psychological fatigue during treatment; the most highly relevant items were “I feel listless” and “I have to limit my social activity because I am tired.” Triangulation of anchor-based, distribution-based, and qualitative-based methods determined a meaningful group-level difference of 2.4 points. Conclusion: The FACIT-Fatigue survey includes items relevant to patients with LA/M BC on taxane-based CT.


  • Open Access

    Human nerve growth factor delivery to the retina: Quantitative methodology and mathematical modeling in preclinical settings

    by Simone L Mattioli, Prashant Dogra, Francesco Longobardi, Grazia Casiello, Lucia Apparente, Nicola Detta, Rubina Novelli, Andrea Aramini, Franca Cattani, Maria I Antonangeli, et al.

    Nerve growth factor (NGF) plays a critical neuroprotective role in retinal health, supporting neuronal survival and regeneration. Recombinant human NGF (rhNGF) holds promise for treating retinal degenerative diseases such as glaucoma, retinitis pigmentosa, and optic neuropathies. However, efficient retinal delivery of rhNGF remains a major challenge due to anatomical barriers and rapid clearance from conventional routes. Here, we integrate in vivo experimentation with mathematical modeling to identify and validate optimized delivery strategies for rhNGF. By using stable isotope-labeled rhNGF, we quantified ocular biodistribution in rats and rabbits following topical eye drops, intravitreal (IVT) injections, and sustained-release formulations. Eye drop administration resulted in negligible retinal exposure (<0.04% of instilled dose), while IVT injection achieved ∼34% vitreous retention with sustained delivery to the retina and optic nerve over 60 days. A mechanistic compartmental model was developed and validated against the in vivo data to simulate route-specific drug transport and estimate delivery losses via a penalty factor (fB). The model identified key parameters governing retinal exposure and guided the design of dose-release profiles to sustain therapeutic concentrations. Controlled-release platforms, such as bioadhesive tablets and gels, exhibited in vitro release rates (0.002–0.015 h⁻¹) aligned with model-predicted requirements for prolonged exposure. Together, these results highlight the importance of route-specific delivery design and demonstrate that combining isotope tracing with mechanistic modeling can quantitatively guide development of long-acting retinal therapeutics. This platform provides a translational framework for optimizing macromolecular drug delivery to the posterior eye.


  • Open Access

    Evaluation of the gastrotolerability of ketoprofen, lysine, and gabapentin co-crystal administration in an in vitro model of gastric epithelium: a proteomic update

    by Francesco D’eGidio, Laura Brandolini, Vanessa Castelli, Massimiliano Quintiliani, Andrea Aramini, Annamaria Cimini, Marcello Allegretti, Michele D’aNgelo

    Chronic pain is a distressful condition that impacts strongly on people’s health, and, to date, no cure has been found. However, several strategies against pain have been proposed. Promising data regarding the usage of nonsteroidal anti-inflammatory drugs (NSAIDs) in combination with gabapentin in pain management laid the foundations for more complex approaches. A recently published study proposed a multimodal approach based on ketoprofen lysine salt (KLS) combined with gabapentin (GABA) in the context of chronic pain. Experiments on in vitro models showed supra-additive effects in modulating key pathways involved in neuropathic pain and gastric mucosal damage. Thus, the co-crystallization of ketoprofen, lysine, and gabapentin led to a new ternary drug-drug co-crystal (KLS-GABA co-crystal) to better take advantage of such effects. The new compound showed positive features in in vitro and in vivo pain models, particularly at the gastrointestinal level. To better understand the gastric impact of the co-crystal we chose to analyze proteomic fluctuations that occur in an in vitro model of gastric epithelium upon ethanol injury, aiming to observe the gastric effects of KLS-GABA co-crystal’s administration in comparison with KLS or GABA alone or co-administered as in the multimodal approach. Thus, we performed a 2-dimensional gel electrophoresis (2DE) to compare proteomes from lysates of NCI-N87 cells, chosen as model of gastric epithelium. Among all the localized spots (n = 117), the differentially abundant ones have been filtered and excised (n = 24) to perform mass spectrometry. A total of 414 non-redundant proteins have been found in the excised spots analyzed. A Gene Ontology-based enrichment analysis identified the proteins involved in biological processes, cellular components, and pathways. We then compared the 2DE findings with the western blot analysis confirming the differential proteomic fluctuations in the model. The methodology described here provides a broader picture of the effects of KLS, GABA, and KLS-GABA co-crystal administration in the ethanol-gastric injury model, identifying processes not revealed by other studies by showing proteomic changes and related mechanisms in detail, particularly via modulation of the oxidative stress-related GSTP1 which suggests the higher gastric tolerability of KLS-GABA co-crystal in the analyzed model highlighting its clinical reliability.


  • Open Access

    Beyond inflammation: the multifaceted therapeutic potential of targeting the CXCL8-CXCR1/2 axis in type 1 diabetes

    by Georgia Fousteri, Meghan Jones, Rubina Novelli, Serena Boccella, Laura Brandolini, Andrea Aramini, Paolo Pozzilli, Marcello Allegretti

    Identifying novel therapeutic targets involved in the multiple mechanisms underlying the complex pathophysiology of type 1 diabetes (T1D) could change the natural history of this disease. The CXCL8-CXCR1/2 axis is emerging as a therapeutic target with a crucial, multifaceted role in T1D pathophysiology. CXCL8-dependent neutrophil chemotaxis to the pancreas precedes autoimmunity, and CXCR1/2 blockade mitigates insulitis and T1D development in preclinical models. In parallel, CXCL8 can act in a β cell-autonomous manner, and exert non-immune actions on adipocytes, hepatocytes, podocytes, and muscle cells that contribute to insulin resistance and diabetic complications. In this review, we delineate compelling evidence of immune and non-immune actions of the axis in the onset and progression of T1D. We show that the CXCL8-CXCR1/2 axis represents a promising therapeutic target for the prevention/reversal of T1D, with a meaningful potential clinical advantage conveyed by its role in multiple components of the pathology and diabetic complications.